#Dana-Farber #TAG1 #Alpha Therapies

TAG1 Partners with Dana-Farber to Boost Alpha Therapy Innovations

In an important move for cancer treatment innovation, TAG1 Inc. has revealed a strategic partnership with the Molecular Cancer Imaging Facility (MCIF) at Dana-Farber Cancer Institute. This collaboration is set to enhance the development of targeted alpha therapies and broaden access to next-generation radioisotopes crucial for fighting cancer.

Aiming for Groundbreaking Cancer Treatment

Both organizations bring their unique strengths to this partnership: Dana-Farber’s leading expertise in radiopharmaceuticals combined with TAG1’s proprietary Pb-212 (Lead-212) generator technology. The goal is clear: to develop and expedite groundbreaking treatment options through an integrated platform for preclinical and clinical advancements.

TAG1's role will involve supplying Lead-212 to Dana-Farber's MCIF, enabling researchers to carry out essential testing of novel compounds that could revolutionize cancer care. This partnership is designed to facilitate both early-stage discoveries and translational research. By providing dependable access to Lead-212, a vital radionuclide in targeted alpha therapies, TAG1 aims to support significant advancements in treatment methodologies.

According to Castor Armesto, TAG1's Chief Strategy Officer, meeting the crucial quality standards for reliably providing preclinical quantities of Lead-212 marks a significant achievement for the company.